148P A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis
Titel:
148P A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis
Auteur:
Han, B. Tian, P. Zhao, Y. Yu, X. Guo, Q. Yu, Z. Zhang, X. Li, Y. Chen, L. Shi, X. Zhang, Y. Wang, J.